Pharma Strategy Blog

"The real tragedy is that the cost of distorted information, and irrational prescribing, is far greater than the cost of the research that could prevent it. Health systems pay for these drugs – state-funded in almost every single developed country – and they largely pay for the journals, too. In a sensible world, countries would band together and pay for comparative research themselves, and the free, open distribution of the results, to prevent all this nonsense."

There are two Informational Modules: MP/H Coding Rules and The SEER Summary Staging Manual. I wish these cancer databases were easier to use or at least remember how to find information easily.

In a different study, in women ages 16 to 26 who were naïve to 14 common HPV types, GARDASIL reduced the number of abnormal Pap test results by 17 to 45 percent, depending on the abnormality, and reduced colposcopies by 20 percent, cervical biopsies by 22 percent and reduced surgery and other invasive treatments by 42 percent.

The International Papillomavirus Conference is the leading conference in the field, encompassing all areas of Papillomavirus research, from clinical vaccinology to molecular biology. New data on Gardasil and Cervarix is expected on HPV vaccines today.

Up until now, there's only been evidence that the series of three shots for the human papillomavirus offers coverage out to five years. The new results from a test on nearly 300 women between 16 and 26 years old indicates the vaccine is still working for, on average, eight-and-a-half years. But overall, protection ranged from 7.2 years to as long as 9.5 years. The findings apply to just one of the four HPV strains covered by Gardasil, but it is one of the strains that is a leading cause of cervical cancer.

Results from the first, large-scale comparative trial between licensed human papillomavirus (HPV) vaccines show that Cervarix® generated a significantly higher immune response compared to Gardasil®. The comparative study looked at two key measures of immune response, neutralising antibodies and memory B cells. Although the post-vaccination immune correlates of protection for cervical cancer are still unknown, neutralising antibodies and B cells are believed to play an important role in protecting women from HPV infection and subsequent cervical cancer over the long term.

Can angiogenesis inhibitors, the famous class of tumor-starving cancer drugs, actually make some kinds of cancer worse?